Bellidifolin Extract Purification for Lower-Toxicity Antidepressants
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antidepressant drugs for depression have significant side effects and require long-term administration, necessitating the development of natural alternatives with less toxicity.
Innovation Solution
Utilizing bellidifolin (BEL) and/or BEL-containing extracts as active ingredients in antidepressant products, prepared through a method involving heating reflux extraction, hydrolysis, salting out, and preparative liquid chromatography to achieve high purity and industrial feasibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemical synthetic antidepressant drugs are used, then depression treatment effectiveness is improved, but side effects increase and toxicity increases
Solution Approach 1:
The patent extracts and utilizes bellidifolin (BEL), a specific natural active ingredient from Gentianaceae plants, to develop an antidepressant product. This extraction approach isolates the beneficial compound from the plant source, providing a targeted natural alternative that avoids the side effects of broad-spectrum chemical synthetic drugs while maintaining treatment effectiveness.
Solution Approach 2:
The patent changes the chemical parameter basis from synthetic chemical compounds to natural plant-derived compounds (bellidifolin). This parameter change in the chemical source fundamentally alters the safety profile while maintaining or improving therapeutic efficacy, directly addressing the contradiction between effectiveness and toxicity.
2Duration of action of stationary object
If chemical antidepressant drugs are administered long-term, then depression treatment is maintained, but cumulative toxicity increases
Solution Approach 1:
By extracting bellidifolin as a specific natural active ingredient, the patent provides a long-term treatment option with a favorable safety profile. The natural origin of BEL allows for sustained administration without the cumulative toxicity issues associated with synthetic antidepressants, enabling prolonged treatment duration.
Solution Approach 2:
The patent utilizes renewable plant resources (Gentianaceae family plants) as the source of bellidifolin. This renewable natural source can be sustainably harvested and processed, providing a continuously available treatment option that does not deplete finite resources and maintains safety over long-term use.
3Object-affected harmful factors
If natural plant extracts are used as antidepressants, then toxicity is reduced, but active ingredient concentration decreases
Solution Approach 1:
The patent employs extraction technology to isolate bellidifolin from Gentianaceae plants, concentrating the active ingredient from the raw plant material. This extraction process overcomes the low concentration problem of crude plant extracts by selectively isolating and concentrating BEL, thereby maintaining low toxicity while achieving high active ingredient concentration.
Solution Approach 2:
The patent changes the concentration parameter of the active ingredient through extraction and purification processes. By transforming the material from crude plant extract to purified bellidifolin, the concentration of the active ingredient is significantly enhanced while the toxic components are removed, resolving the contradiction between concentration and toxicity.
4Manufacturing precision
If complex extraction and purification processes are used, then active ingredient purity is improved, but manufacturing complexity increases
Solution Approach 1:
The patent utilizes extraction technology to isolate bellidifolin from plant materials, achieving high purity through selective extraction. This approach achieves manufacturing precision by targeting the specific active ingredient while simplifying the overall process compared to more complex purification methods, as the natural properties of BEL enable effective separation.
Data Source
AI summary
Use of bellidifolin (BEL) and/or a BEL-containing extract in preparation of an antidepressant product is provided, belonging to the technical field of medicine. The BEL or BEL-containing extract as an active ingredient can significantly improve a depressive behavior of mice, regulate concentrations of 5-hydroxytryptamine (HT) and corticosterone (CORT), protect nerve cells, and improve synaptic plasticity. Moreover, the BEL or BEL-containing extract can penetrate the blood-brain barrier (BBB) and has a significant effect on improving and treating depression. In addition, a method for preparing the BEL-containing extract has the advantages of simple operation, low cost, and desirable repeatability and stability. BEL in the extract has a concentration of up to 1.0% to 95.0%. After purifying the BEL-containing extract, the BEL has a high purity of up to 95.0% to 99.9%, and is easy to realize industrial production during the preparation.